



CCRM announces Dr. Sven Kili as first Chief Development Officer and changes to its Board of Directors

January 17, 2024 (Toronto, ON) – CCRM is pleased to announce strategic changes to its leadership team and Board of Directors, reinforcing its commitment to innovation and growth.

Sven Kili, MD, has joined CCRM as its new Chief Development Officer and will be providing strategic guidance to OmniaBio Inc., CCRM's CDMO subsidiary. With a proven track record of driving successful development strategies, Kili will play a pivotal role in advancing CCRM's technical platforms in induced pluripotent stem cells, immunotherapies and lentiviral vectors in addition to guiding the creation and development of new companies in CCRM's incubation program. He will oversee CCRM's growth and development by identifying opportunities for expansion, establishing partnerships, and driving initiatives to enhance the organization's overall performance.

Kili was formerly CEO of Antion Biosciences, where he built an academic team into a financed development company focused on engineered CAR-T therapies. Prior to that, he was Head of Development for the CGT division of GSK Rare Diseases, where he led teams developing and commercializing gene therapies for a variety of rare genetic disorders. Kili steps down as a member of CCRM's Board of Directors.

CCRM is also excited to announce that Phil Vanek, PhD, Chief Technology Officer at Gamma Biosciences, will serve as a Director of [CCRM Enterprises Inc.](#) and CCRM Enterprises Holdings Ltd. Vanek's wealth of experience and industry knowledge will contribute to the continued expansion of CCRM Enterprises, which is CCRM's for-profit venture investment arm. This announcement marks the end of his tenure on CCRM's Board of Directors.

Catarina Flyborg has taken on a new role as a Director on the Board of [CCRM Nordic](#), the Sweden-based CCRM hub that was announced in May 2023. Her dedication and contributions to CCRM's global vision make her a valuable addition to the Nordic team's operations. Flyborg, Strategic Advisor and former Vice President Cell and Gene Therapy at Cytiva, will no longer serve on CCRM's Board of Directors.

"These recent changes to the leadership and Boards across CCRM and the CCRM Group of Companies underscore our dedication to assembling a dynamic and experienced leadership team," says Michael May, President and CEO, CCRM. "Together, we look forward to achieving new milestones and propelling our organizations, and the regenerative medicine sector as a whole, to greater success."

In tandem with these appointments, CCRM announces the following additions to its Board of Directors:

- Dozie Amuzie, Head, Johnson & Johnson Innovation-JLABS, Canada;

- Abi Coman-Walker, Chief Operating Officer, Acuitas Therapeutics; and,
- Emmanuel Abate, President, Genomic Medicine, Cytiva.

CCRM would like to thank those who have contributed their valuable time, insights and expertise to CCRM's Board of Directors during their committed terms. In addition to the recent departures from its Board as noted above, the Board term of Donna Wall, Section Head, Blood and Marrow Transplant/Cellular Therapy, Division of Hematology/Oncology, The Hospital for Sick Children, has also ended.

About CCRM

CCRM is a global, public-private partnership headquartered in Canada. It has received funding from the Government of Canada, the Province of Ontario, and leading academic and industry partners. CCRM supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy. A network of researchers, leading companies, investors, and entrepreneurs, CCRM accelerates the translation of scientific discovery into new companies and marketable products for patients with specialized teams, dedicated funding, and unique infrastructure. In 2022, CCRM established OmniaBio Inc., a commercial-stage CDMO for manufacturing cell and gene therapies. CCRM is hosted by the University of Toronto. Visit us at ccrm.ca.

-30-

For more information, please contact:

Stacey Johnson
Vice President, Communications and Marketing
stacey.johnson@ccrm.ca
1-647-309-1830